齐拉西酮与氟哌啶醇治疗精神分裂症对照研究(1)
http://www.100md.com
2010年3月15日
 |
| 第1页 |
参见附件(1683KB，3页)。
[摘要] 目的:探讨齐拉西酮治疗精神分裂症的疗效及不良反应。方法:将符合入组标准的100例精神分裂症患者随机分为齐拉西酮组与氟哌啶醇组各50例,进行为期8周的治疗。采用阳性与阴性症状量表(PANSS)评定疗效、副反应量表(TESS)评定副反应。结果:氟哌啶醇组有效率为74%,显效率为38%;齐拉西酮组有效率为84%,显效率为72%。两组药物显效率比较,差异有统计学意义(P<0.01);阳性与阴性症状量表评分,两组治疗第4周末起总分及各因子分与治疗前比较,差异有统计学意义(P均<0.01)。结论:该两种药物对精神分裂症均有确切疗效,且安全性相对较高,齐拉西酮对症状的改善效果更好,不良反应轻微。
[关键词] 齐拉西酮;氟哌啶醇;精神分裂症
[中图分类号] R971+.41 [文献标识码]B [文章编号]1674-4721(2010)03(b)-050-03
A comparative study of ziprasidone and haloperidol in the treatment for schizophrenia
LIU Xianbiao,ZHANG Yuliang,HE Lanying,WU Chunxiang
(Department of Psychiatry, the Third People's Hospital of Meizhou City, Guangdong Province, Meizhou 514089, China)
[Abstract] Objective: To explore the effect and adverse reactions of ziprasidone in the treatmet of schizophrenia. Methods:100 cases of schizophrenia conforming to standard were randomly divided into ziprasidone group and haloperidol group for eight weeks. The efficiency and adverse reactions were assessed with positive and negative syndrome scale(PANSS) and treatment emergent symptom scale(TESS) respectively. Results: There were no significant differeces between haloperidol group and ziprasidone group in improved(74% vs 84%) and markedly response rate(38% vs 72%). The efficiency of the two groups had significantly differences(P<0.01). Had given four weeks medical care to both groups of the positive and negative syndrome scale(PANSS), The author got a total score and the factor scores in a very significant difference from those before treatment(P<0.01). Conclusion: The two drugs have an accurate effect on schizophrenia,and the security is relatively high,while ziprasidone is a bit better in symptom improvement and its adverse reactions are mild.
[Key words] Ziprasidone;Haloperidol;Schizophrenia
齐拉西酮为二环类非典型抗精神病药,对多巴胺D2、D3、5-HT2A、5-HT2C、5-HT1A、5-HT1D及α1-肾上腺素素能受体均具有较高的亲和力,对组胺H受体具有中等亲和力;并对D2、5-HT2A、5-HT1D受体具有拮抗作用,对5-HT1A受体具有激动作用;能抑制突触对5-羟色胺和去甲肾上腺素的再摄取,从而改善精神分裂症的阴性症状[1]。与已上市的典型及非典型抗精神病药相比,它对精神病阴性症状的疗效更好,发生锥体外系反应和体重增加等不良应的概率很小,因而具有广阔的市场前景。齐拉西酮是一种新型非典型抗精神病药,在国外临床应用多年。国外研究资料表明,该药对精神分裂症的阳性、阴性症状均有良好疗效,且患者的依从性及耐受性均较好。为验证该药治疗精神分裂症患者的疗效及安全性,笔者以氟哌啶醇为对照进行了开放性研究,现报道如下: ......
您现在查看是摘要介绍页，详见PDF附件(1683KB，3页)。